Amgen Inc.

🇺🇸NASDAQ Global Select
Back to all articles
Amgen Inc. stock analysis AMGN overview
Slightly Bullish +25

Amgen Insiders Sell US$4.1m Of Stock, Possibly Signalling Caution

📉 Multiple Amgen insiders have offloaded shares over the past year, totaling US$4.1 million in sales.

🏢 The largest single insider sale was by Executive Vice President Murdo Gordon, who sold US$2.3m worth of stock.

💰 Murdo Gordon sold his shares at US$337 per share, which is slightly below the current market price of US$346.

📊 In recent months, Chief Accounting Officer Matthew Busch dumped an additional US$376k worth of shares without any accompanying purchases.

❌ Amgen insiders recorded zero stock purchases over the last twelve months and the last three months combined.

🤝 Insiders collectively own only 0.2% of Amgen's shares, holding approximately US$311m in total value based on recent pricing.

⚠️ While insider selling is not always definitive, the combination of no buying activity and sales below current price signals caution.

📈 Despite the negative insider sentiment, analysts note that Amgen remains profitable and growing, which mitigates some concern.

🕸️ The article highlights a single specific warning sign regarding insider transactions before investors consider purchasing shares.

🔍 Open market and private direct interest transactions are tracked, but derivative trades and indirect interests are excluded from the analysis.

Bullish Signals
  • Amgen remains profitable and growing, which alleviates concerns about the recent insider selling activity.
  • The company maintains a strong insider ownership base of 0.2%, indicating that management is incentivized to focus on long-term shareholder interests.
  • Recent sales by insiders were only partial holdings; for instance, the largest single sale represented just 19% of Murdo Gordon's total holding.
  • Insider transactions account for only open market and private dispositions, excluding derivatives which might offer additional strategic flexibility.
Risk Factors
  • Multiple insiders, including Executive Vice President Murdo Gordon and Chief Accounting Officer Matthew Busch, have sold shares totaling US$3.476m in the last year without any corresponding purchases, signaling potential lack of confidence.
  • Insider sales often occur at prices below the current market value; for example, Murdo Gordon sold US$2.3m worth of shares at US$337 per share, slightly below the current price of US$346, suggesting insiders may consider the stock less valuable than the market does.
  • Amgen insiders currently own only 0.2% of the company, indicating weak alignment with shareholders and minimal incentive for management to prioritize long-term stock growth over other interests.
Full Analysis
Amgen insiders have been actively selling shares over the last 12 months, with no corresponding purchases recorded, which may signal some caution from management. The largest single transaction involved Executive Vice President of Global Commercial Operations Murdo Gordon, who sold US$2.3 million worth of stock at a price of $337 per share, slightly below the current market price of approximately $346. In addition to Gordon's sale, Chief Accounting Officer & VP of Finance Matthew Busch sold US$376,000 worth of shares over the last three months. These transactions collectively indicate that insiders are offloading holdings without replenishing them, a pattern some investors might interpret as a belief that the stock is not undervalued. Despite this selling activity, the article notes that Amgen insiders own only 0.2% of the company, which equates to roughly US$311 million in total value based on recent share prices. While low insider ownership can sometimes be a concern, the analysts argue it does suggest some alignment of interests, though they remain slightly cautious due to the lack of buying and recent selling below current valuations. The company is described as profitable and growing, which mitigates the negative sentiment surrounding the insider sales somewhat. Overall, the content highlights that while insider transactions are important metrics, they must be viewed in context alongside other factors like profitability and growth. The article serves as a cautionary tale for investors to monitor insider behavior but advises against overreacting to selling alone if the fundamentals remain strong. It also includes standard disclaimers about the analysis being based on historical data and not constituting financial advice.